Pharmacogenomics of interferon-β therapy in multiple sclerosis: Baseline IFN signature determines phamacological differences between patients

PLoS ONE

Volumn 3, Issue 4, 2008, Pages

  van Baarsen, Lisa G M ^a   Vosslamber, Saskia ^a   Tijssen, Marianne ^a   Baggen, Josefien M C ^a   van der Voort, Laura F ^a   Killestein, Joep ^a   van der Pouw Kraan, Tineke C T M ^a   Polman, Chris H ^a   Verweij, Cornelis L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; INTERFERON;

ADULT; ARTICLE; CELL ISOLATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENOMICS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; COHORT ANALYSIS; CYTOLOGY; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL; PHARMACOGENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

ADULT; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; INTERFERONS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 44849128066     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001927     Document Type: Article

References (36)

1. Hafler DA, Slavik JM, Anderson DE, O'Connor KG, De JP, et al. (2005) Multiple sclerosis. Immunol Rev 204: 208-231.
2. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45: 1277-1285.
3. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56: 548-555.
4. Reske D, Walser A, Haupt WF, Petereit HF (2004) Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol Scand 109: 66-70.
5. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, et al. (1999) The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 52: 1277-1279.
6. Sibley WA, Bamford CR, Clark K (1985) Clinical viral infections and multiple sclerosis. Lancet 1: 1313-1315.
7. Vartanian TK, Zamvil SS, Fox E, Sorensen PS (2004) Neutralizing antibodies to discase-modifying agents in the treatment of multiple sclerosis. Neurology 63: S42-S49.
8. Ghislain JJ, Fish EN (1996) Application of genomic DNA affinity chromatography identifies multiple interferon-alpha-regulated Stat2 complexes. J Biol Chem 271: 12408-12413.
9. Li X, Leung S, Qureshi S, Darnell JE Jr., Stark GR (1996) Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha. J Biol Chem 271: 5790-5794.
10. Brierley MM, Fish EN (2005) Functional relevance of the conserved DNA-binding domain of STAT2. J Biol Chem 280: 13029-13036.
11. Ghislain JJ, Wong T, Nguyen M, Fish EN (2001) The interferon-inducible Stat2:Stat1 heterodimer preferentially binds in vitro to a consensus element found in the promoters of a subset of interferon-stimulated genes. J Interferon Cytokine Res 21: 379-388.
12. Takaoka A, Taniguchi T (2003) New aspects of IFN-alpha/beta signalling in immunity, oncogenesis and bone metabolism. Cancer Sci 94: 405-411.
13. Der SD, Zhou A, Williams BR, Silverman RH (1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95: 15623-15628.
14. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, et al. (2006) A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 7: 522-531.
15. van der Pouw Kraan TC, Baarsen EGM, Rustenburg F, Baltus B, Fero M, et al. (2007) Gene expression profiling in rheumatology. In: Cope AP, ed (2007) Arthritis Research The Humana Press Inc., pp..
16. Ball CA, Awad IA, Demeter J, Gollub J, Hebert JM, et al. (2005) The Stanford Microarray Database accommodates additional microarray platforms and data formats. Nucleic Acids Res 33: D580-D582.
17. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
18. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
19. Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, et al. (2005) Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 158: 195-203.
20. Markowitz CE (2007) Interferon-beta: mechanism of action and dosing issues. Neurology 68: S8-11.
21. Revel M (2003) Interferon-beta in the treatment of relapsing-remitting multiple sclerosis. Pharmacol Ther 100: 49-62.
22. Kracke A, von WP, Al-Masri AN, Dalley G, Windhagen A, et al. (2000) Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 54: 193-199.
23. Alam J, Goelz S, Rioux P, Scaramucci J, Jones W, et al. (1997) Comparative pharmacokinetics and pharmacodynamicsof two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers, Pharm Res 14: 546-549.
24. Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, et al. (1999) A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Clin Cancer Res 5: 3990-3998.
25. Salmon P, Le Cotonnec JY, Galazka A, bdul-Ahad A, Darragh A (1996) Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 16: 759-764.
26. Sturzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B (1999) Pharmacodynamic comparison of single doses of IFN-beta 1a and IFN-beta 1b in healthy volunteers. J Interferon Cytokine Res 19: 1257-1264.
27. Baranzini SE, Mousavi P, Rio J, Caillier SJ, Stillman A, et al. (2005) Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol 3: e2.
28. Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, et al. (2003) Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 171: 2694-2702.
29. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, et al. (2003) Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 126: 1419-1429.
30. Zhuang H, Kosboth M, Lee P, Rice A, Driscoll DJ, et al. (2006) Lupus-like disease and high interferon levels corresponding to trisomy of the type I interferon cluster on chromosome 9p. Arthritis Rheum 54: 1573-1579.
31. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, et al. (2002) Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 129: 205-215.
32. Gresser I (1990) Biologic effects of interferons. J Invest Dermatol 95: 66S-71S.
33. Dupont SA, Goelz S, Goyal J, Green M (2002) Mechanism for regulation of cellular responsiveness to human IFN-beta 1a. J Interferon Cytokine Res 22: 491-501.
34. Lehtonen A, Matikainen S, Julkunen I (1997) Interferon up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J Immunol 159: 794-803.
35. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125: 1676-1695.
36. Rudick RA, Lee JC, Simon J, Fisher E (2006) Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann Neurol 60: 236-242.